

Amendments to the Specification:

Please replace paragraph [0081] with the following amended paragraph:

[0081] These compounds 4 and 5 show remarkable anti-prostate cancer activity. The biological testing was carried out by measurement of the amount of prostate-specific antigen (PSA) produced by LNCaP cells. The IC₅₀ values of 4 and 5 for PSA expression are ten-fold lower than that for bicalutamide (2-3 times stronger) and the compounds seem to be full antagonists. Therefore they offer the potential for a better drug for the treatment of prostate cancer, namely they antagonize the effect of androgens on the AR and thus should greatly slow the progression of prostate cancer.